• Skip to primary navigation
  • Skip to main content
  • Skip to footer
Show Search
Home
EN / FR
  • LinkedIn
  • Twitter
Celyad Oncology

Celyad Oncology

  • About Us
    • Overview
    • Management Team
    • Board Of Directors
    • Partners
  • Science
    • Overview
    • Approach
    • Technology
      • TIM
      • shRNA
      • shARC Platform
    • Manufacturing
    • Scientific Publications
  • Pipeline
  • Newsroom
    • Press Releases
    • Events
    • Media Center
  • Investors
    • Overview
    • Analyst Coverage
    • Corporate Governance
    • Regulated Information
    • Shareholders Information
    • Shareholders Meeting
  • Careers
  • Contact Us

Information on the Total Number of Voting Rights and Shares (Article 15 of the Law of 2 May 2007)

March 31, 2021 By Celyad Oncology

Mont-Saint-Guibert, Belgium – Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, announced on March 29, 2021 a capital increase of 200,000 new shares of the Company to Lincoln Park Capital Fund, LLC (“LPC”), a Chicago-based institutional investor. As a result, the Company’s share capital is increased to 50,123,200.33 EUR and is represented by 14,405,156 shares.

This information is published in accordance with Article 15 of the Belgian Law of 2 May 2007 on the disclosure of major participations in issuers whose shares are admitted to trading on a regulated market and regarding miscellaneous provisions.

Figures – Modified on 29 March 2021 following the Capital Increase.

Total amount of share capital (EUR)50,123,200.33
Total Number of shares with single voting rights14,332,832
Total Number of shares with double voting rights72,324
Total Number of Shares14,405,156
Total of voting rights14,477,480
Total number of attributed warrants1,734,439
Total number of shares with voting rights that could be created following the exercise of the attributed warrants1,734,439
Total number of diluted shares (Outstanding shares + Warrants)16,139,595
Total number of diluted shares with voting rights16,211,919

Contact person for regulated information (financial, transparency)

By law, any transparency declaration must be sent to our Company by email to the attention of Filippo Petti, Chief Executive Officer (CEO): investors@celyad.com.

Further questions about the content of this release can be sent to investors@celyad.com.

Download press release(s)
Communiqué de presse
Press Release

Filed Under: Uncategorized

Footer

Celyad Oncology Logo
  • About
  • Science
  • Pipeline
  • Newsroom
  • Investors
  • Contact Us
  • LinkedIn
  • Twitter

Copyright © 2020 All Rights Reserved.
Cookie Policy | Privacy Policy | Terms of Use